Manu Chakravarthy
Chief Tech/Sci/R&D Officer at Carmot Therapeutics, Inc.
Profile
Manu Chakravarthy is currently the Chief Scientific & Medical Officer at Carmot Therapeutics, Inc. He previously worked as the Global Head-External Research & Development at Eli Lilly & Co. from 2015 to 2017 and as the Chief Medical Officer & SVP-Clinical Development at Axcella Health, Inc. from 2017 to 2021.
Chakravarthy received his undergraduate degree from Saint John's University in 1995 and his doctorate from the University of Texas Graduate School of Biomedical Sciences and The University of Texas Medical School At Houston.
Manu Chakravarthy active positions
| Companies | Position | Start |
|---|---|---|
Carmot Therapeutics, Inc.
 Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | Chief Tech/Sci/R&D Officer | 28/02/2021 |
Former positions of Manu Chakravarthy
| Companies | Position | End |
|---|---|---|
| AXCA HEALPAR | Chief Tech/Sci/R&D Officer | 04/03/2021 |
| ELI LILLY AND COMPANY | Corporate Officer/Principal | 31/05/2017 |
Training of Manu Chakravarthy
| Saint John's University | Undergraduate Degree |
| University of Texas Graduate School of Biomedical Sciences | Doctorate Degree |
| The University of Texas Medical School At Houston | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| ELI LILLY AND COMPANY | Health Technology |
| AXCA HEALPAR | Health Technology |
| Private companies | 1 |
|---|---|
Carmot Therapeutics, Inc.
Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | Health Technology |
- Stock Market
- Insiders
- Manu Chakravarthy
